Results 91 to 100 of about 2,791 (213)
Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper
ABSTRACT Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways ...
Maria J. Torres +19 more
wiley +1 more source
CHILD WITH JOINT PAIN – CLINICAL VIGNETTES
Joint pain is a common clinical symptom in children with a broad and diverse etiology – ranging from benign, self-limiting conditions to serious and potentially life-threatening diseases.
Maša Bizjak
doaj +1 more source
Arthralgia (arthritis).Advances on diagnosis and treatment.II...Epidemiology of arthralgia.
関節痛を主訴とするリウマチ病の疫学研究の中から, RA,変形性関節症,肩痛症,強直性脊椎炎,若年性関節リウマチ,痛風,結合組織病, Lyme病について,日本と外国との成績を比較して紹介した.変形性関節症,痛風,若年性関節リウマチでは,外国と大差はないが,慢性関節リウマチ,強直性脊椎炎では低頻度で,結合組織病ではむしろ多いかもしれない.環境因子,素因についての研究は,今後の進展を期待する.
openaire +2 more sources
ABSTRACT Aim To provide an update paper on evidence of adverse events of concern following immunization (AEFI) with pertussis vaccines, focusing primarily on acellular (aP) vaccines. Methods Evidence was synthesised from epidemiological studies, systematic reviews over recent decades, expert interpretations in reviews from relevant research teams and ...
Lennart Nilsson, Jann Storsaeter
wiley +1 more source
In the POISE open‐label extension, patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid received long‐term obeticholic acid (OCA) treatment. Findings demonstrated a safety profile consistent with the known characteristics of OCA, with no unexpected safety signals, while supporting sustained efficacy ...
Christopher L. Bowlus +8 more
wiley +1 more source
Summary Haemoglobin SC (HbSC) disease is the second most prevalent form of sickle cell disease, but evidence for hydroxyurea (hydroxycarbamide; HU) to prevent pain episodes was limited until the prospective identification of variables as outcomes for treatment (PIVOT) trial.
Alice Girard +10 more
wiley +1 more source
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo +3 more
wiley +1 more source
Chronic Pruritic Papular Eruption in an Elderly Man
JEADV Clinical Practice, EarlyView.
Filipe Monteiro +6 more
wiley +1 more source
Minimal residual disease (MRD)–guided ibrutinib and venetoclax (IVen) achieved durable remissions and high undetectable MRD (uMRD) rates in patients with high‐risk chronic lymphocytic leukaemia (CLL). Compared with historical ibrutinib monotherapy, IVen was associated with improved progression‐free and overall survival despite presence of complex ...
Maria Kislova +15 more
wiley +1 more source

